757 Participants Needed

Adapt2Quit Motivational System for Quitting Smoking

(A2Q Trial)

Recruiting at 2 trial locations
AK
LM
RM
Overseen ByReem M Najjar
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University of Massachusetts, Worcester
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 1 JurisdictionThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

This trial tests a computer program called Adapt2Quit that sends personalized motivational texts to help socioeconomically disadvantaged smokers quit. The program uses user feedback to choose the most motivating messages.

Do I have to stop taking my current medications to join the trial?

The trial protocol does not specify whether you need to stop taking your current medications.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It seems focused on smoking cessation through motivational messages, so it's unlikely that your medications would be affected.

What data supports the idea that Adapt2Quit Motivational System for Quitting Smoking is an effective treatment?

The available research does not provide specific data on the effectiveness of the Adapt2Quit Motivational System for Quitting Smoking. However, it does mention the effectiveness of another treatment, the Pathways to Change system, which is an expert system intervention for smoking cessation. This system showed cessation rates of 22 to 26% in a general population, with increasing effects over time. This suggests that expert system interventions, like Adapt2Quit, could potentially be effective in helping people quit smoking.12345

What data supports the effectiveness of the Adapt2Quit treatment for quitting smoking?

The Pathways to Change system, an expert system intervention similar to Adapt2Quit, has shown success in helping people quit smoking, with cessation rates of 22 to 26%. This suggests that expert system interventions can be effective in supporting smoking cessation.12345

What safety data is available for the Adapt2Quit smoking cessation treatment?

The provided research does not directly mention safety data for the Adapt2Quit treatment or its variants. The studies focus on other smoking cessation methods, such as smartphone applications, electronic cigarettes, text messaging programs, and chat-bots, but do not provide specific safety data for Adapt2Quit.678910

Is the Adapt2Quit treatment a promising way to quit smoking?

The Adapt2Quit treatment seems promising because similar systems, like SmartQuit and Text2Quit, have shown success in helping people quit smoking. These systems use technology to provide support and advice, which can make quitting easier and more effective.58111213

How is the Adapt2Quit treatment different from other smoking cessation treatments?

The Adapt2Quit Motivational System for Quitting Smoking is unique because it likely combines personalized motivational strategies with technology to help individuals quit smoking, setting it apart from other treatments like smartphone apps or text messaging programs that focus on behavioral therapy or automated support.58111213

Research Team

RS

Rajani Sadasivam, PhD

Principal Investigator

Associate Professor

Eligibility Criteria

This trial is for English-speaking adults who smoke, have had at least two clinical visits in the past year, and are socioeconomically disadvantaged. They must own a texting-enabled cell phone. Pregnant women, prisoners, those unable to consent, minors, and previous pilot study participants cannot join.

Inclusion Criteria

Active in care (at least two clinical visits in the last year)
You are currently smoking.
You are unemployed or underemployed, low income as defined by the federal poverty level guidelines, uninsured or underinsured, and/or have less than a high school education.
See 1 more

Exclusion Criteria

Pilot study participants
I am unable to give consent for medical procedures.
Pregnant women
See 2 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive Adapt2Quit motivational messaging and quitline facilitation messaging or quitline facilitation-only messaging for 6 months

6 months
Ongoing text message interactions

Follow-up

Participants are monitored for smoking cessation outcomes, including biochemical CO verification and self-reported cessation rates

6 months post-randomization

Treatment Details

Interventions

  • Adapt2Quit
Trial Overview The Adapt2Quit program is being tested against a control that only facilitates quitline use via text messages. The program sends motivational texts tailored to help users quit smoking based on their feedback on message effectiveness.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Adapt2QuitExperimental Treatment1 Intervention
These participants will receive Adapt2Quit motivational messaging and quitline facilitation messaging for 6 months.
Group II: ControlActive Control1 Intervention
These participants will receive quitline facilitation-only messaging for 6 months.

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Massachusetts, Worcester

Lead Sponsor

Trials
372
Recruited
998,000+

Johns Hopkins University

Collaborator

Trials
2,366
Recruited
15,160,000+

National Cancer Institute (NCI)

Collaborator

Trials
14,080
Recruited
41,180,000+

Baystate Health

Collaborator

Trials
9
Recruited
54,500+

National Institutes of Health (NIH)

Collaborator

Trials
2,896
Recruited
8,053,000+

Findings from Research

The fidelity index developed to measure the delivery of a smoking cessation behavioral support intervention showed good reliability, indicating it can effectively assess how well providers adhere to and interact during the sessions.
Higher quality of interaction during the sessions was linked to better quit rates among participants, while strict adherence to the content was associated with lower quit rates, suggesting that the way support is delivered may be more important than simply following the content guidelines.
Measuring fidelity to behavioural support delivery for smoking cessation and its association with outcomes.Dogar, O., Boehnke, JR., Lorencatto, F., et al.[2021]
Nicotine mini-lozenges can increase smoking abstinence rates in individuals who are initially unwilling to quit, achieving a 16.7% abstinence rate when used alone.
However, when combined with reduction counseling, the effectiveness of the mini-lozenge significantly decreases, leading to a much lower abstinence rate of 4.1%, and reduction counseling itself reduces the likelihood of making a quit attempt.
Evaluating four motivation-phase intervention components for use with primary care patients unwilling to quit smoking: a randomized factorial experiment.Cook, JW., Baker, TB., Fiore, MC., et al.[2022]
In a study of 513 smokers, electronic monitoring and counseling significantly increased the use of nicotine gum, but this did not lead to higher rates of smoking abstinence.
Adherence to both the nicotine patch and gum during the first 6 weeks of a quit attempt was strongly associated with higher rates of abstinence at 1 year, suggesting that consistent use of these aids may be crucial for successful quitting.
Can we increase smokers' adherence to nicotine replacement therapy and does this help them quit?Schlam, TR., Cook, JW., Baker, TB., et al.[2019]

References

Measuring fidelity to behavioural support delivery for smoking cessation and its association with outcomes. [2021]
Evaluating four motivation-phase intervention components for use with primary care patients unwilling to quit smoking: a randomized factorial experiment. [2022]
Can we increase smokers' adherence to nicotine replacement therapy and does this help them quit? [2019]
Assessing motivation to smoking cessation in hospitalized patients. [2021]
An expert system intervention for smoking cessation. [2022]
Effectiveness of a chat-bot for the adult population to quit smoking: protocol of a pragmatic clinical trial in primary care (Dejal@). [2020]
How do text-messaging smoking cessation interventions confer benefit? A multiple mediation analysis of Text2Quit. [2018]
Single-arm trial of the second version of an acceptance & commitment therapy smartphone application for smoking cessation. [2023]
Piloting a clinical laboratory method to evaluate the influence of potential modified risk tobacco products on smokers' quit-related motivation, choice, and behavior. [2021]
Analysing user-reported data for enhancement of SmokefreeTXT: a national text message smoking cessation intervention. [2018]
Patterns of use of an automated interactive personalized coaching program for smoking cessation. [2022]
12.United Statespubmed.ncbi.nlm.nih.gov
Using SmartQuit®, an Acceptance and Commitment Therapy Smartphone application, to reduce smoking intake. [2022]
A randomized trial of Text2Quit: a text messaging program for smoking cessation. [2022]